Dr Andrew Revell has more than 25 years' experience working in the field of HIV and AIDS. Dr Revell has a PhD in Psychopharmacology from the University of Reading in the UK and is a Chartered Psychologist. He joined Wellcome in 1988 working in medical communications on the first HIV drug, AZT and working closely with Dr Larder in clinical virology. In 1990 he started Wellcome’s pioneering HIV community relations work, developing international, regional and national community advisory boards and involving treatment activists in the design of clinical trials. In 1991 he developed and launched Wellcome’s global programme of HIV education, care and community support, Positive Action, which continues to this day.
In 1996, Dr Revell joined the global medical communications group MediTech Media as a director and set-up their public affairs arm. In 2000 Dr Revell rejoined Dr Larder as Communications Director at Virco, before becoming Vice President of Corporate Communications at Visible Genetics. Dr Revell worked with Dr Larder on the foundation of RDI in 2001, becoming its Executive Director in 2002.